The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
about
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.HIV-1 reverse transcriptase dissociates during strand transfer.HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeSubtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyMechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
P2860
Q28478993-3052AB39-A58B-413B-B11D-2AE635355160Q28537608-64A392A5-7017-447A-8D17-89C03AB930E0Q33681279-373BB40D-BA80-49C4-B4CD-29D3DA61AE7EQ34058254-B7FAF240-8D3E-4BB4-A7F6-114AE6CC3FE8Q35105821-765E2E02-759D-40C4-A797-5D0F9E3977D4Q35196343-1857FF41-B47B-4276-AB75-9B5019097B90Q35536296-AF9969E5-15FC-47FA-9F8D-122A8CA09A8EQ35607740-3F26F71C-D1AA-4886-825E-FD8610AE6A50Q36076011-07BB584F-9F0B-4F5B-ACE1-9254E6D9ED2CQ37146567-9D7231C4-D2EA-4A9D-9320-9EC581B8D87AQ37470030-5659BD91-E408-482E-82D5-089CF8571187Q38356685-F9AE3711-D6CD-46C4-925F-E4FB093978A8Q41820283-FE0D9BFF-8B4D-4FC7-8AE9-3239DA77818AQ42430831-93C5E5C6-8831-48B3-98EE-B83739FBB9F4Q42738819-E9A32270-5644-4631-8590-0B4C742B9742Q52374199-DE46C418-AFC8-4524-BF0A-10262CA29F47
P2860
The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@en
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@nl
type
label
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@en
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@nl
prefLabel
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@en
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@nl
P2093
P2860
P1476
The balance between NRTI discr ...... ts K65R, M184V and K65r+M184V.
@en
P2093
Holly L MacArthur
Kirsten L White
Magdeleine Hung
Michael D Miller
Nicolas A Margot
P2860
P304
P356
10.1177/095632020701800603
P577
2007-01-01T00:00:00Z